Viewing nowPlinda Capsule 75 mg (Pregabalin)
Pregabalin 75mg
Hard capsule · Prescription medication
BC World Pharma Co., Ltd.

MFDS item code 201109143 · Approved 2011.10.25 · Insurance code 653102570
Treatment of neuropathic pain, treatment of fibromyalgia, adjunctive treatment of partial-onset seizures
This medication is used effectively for the treatment of peripheral and central neuropathic pain in adults. It is also utilized as an adjunctive treatment for partial seizures in patients with epilepsy, whether or not secondary systemic symptoms are present. It is additionally used to alleviate the symptoms in patients with fibromyalgia. Overall, it is a useful drug for the management of various neurological diseases and pain.
Administer the total daily dose of this medicine, as pregabalin, orally in 2 divided doses, regardless of food. This medicine is primarily excreted by the kidneys; therefore, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) Peripheral neuropathic pain Adults: An initial dose of 150mg/day may be administered. Based on each patient's response and tolerability, the dose may be increased to 300mg/day after 3 to 7 days. If necessary, it may then be increased at 7-day intervals to a maximum of 600mg/day. Central neuropathic pain Adults: An initial dose of 150mg/day may be administered. Based on each patient's response and tolerability, the dose may be increased to 300mg/day after 1 week. After an additional week, it may be increased to the target daily dose of 600mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’.) Epilepsy Adults: An initial dose of 150mg/day may be administered. Based on each patient's response and tolerability, the dose may be increased to 300mg/day after 1 week. If necessary, it may then be increased at 7-day intervals to a maximum of 600mg/day. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300mg∼450mg/day. The initial dose is 75mg twice daily (150mg/day); based on efficacy and tolerability, it may be increased within 1 week to 150mg twice daily (300mg/day). For patients who do not experience sufficient benefit at 300mg/day, the dose may be increased within 1 week to 225mg twice daily (450mg/day). Clinical studies have also been conducted at a dose of 600mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450mg/day are not recommended. Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over a period of at least 1 week. Patients with renal impairment This medicine is primarily excreted by the kidneys in unchanged form after passing into the systemic circulation. Since its clearance is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance ≥60 mL/min: initial dose 150mg/day, maximum dose 600mg/day, BID or TID Creatinine clearance ≥30∼<60 mL/min: initial dose 75mg/day, maximum dose 300mg/day, BID or TID Creatinine clearance ≥15∼<30 mL/min: initial dose 25∼50mg/day, maximum dose 150mg/day, QD or BID Creatinine clearance <15 mL/min: initial dose 25mg/day, maximum dose 75mg/day, QD Supplemental dose after hemodialysis: initial dose 25mg, maximum dose 100mg, single dose * : For women, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Once daily a : The total daily dose (mg/day) should be divided as specified by the dosing regimen. b : A supplemental dose refers to an additional dose given once. No dose adjustment is necessary in patients with hepatic impairment. Elderly patients (65 years of age or older) Dose reduction may be necessary in elderly patients with impaired renal function.
Children under 12 years of age: Use is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12∼17 years: Use is not recommended because there are insufficient safety and efficacy data.
This medication may increase the risk of suicidal thoughts or behaviors, so if any symptoms of depression or mood changes occur, it should be reported to a healthcare provider immediately. This medication should not be taken if there is hypersensitivity to it or specific genetic lactose-related disorders. Diabetes patients may be affected in blood sugar control due to weight gain, and adjustments in the dosage of blood sugar medications may be necessary. If symptoms of angioedema occur, discontinue the medication immediately, and caution is required in the elderly due to the risk of accidents from dizziness or drowsiness. Visual changes such as blurred vision may occur, and if any abnormal symptoms arise, consulting a healthcare provider is necessary. Discontinuing this medication abruptly may lead to withdrawal symptoms such as insomnia, headache, and anxiety, so it should be tapered off gradually after consulting a specialist. Patients with a history of drug abuse may have a higher risk of misuse of this medication, so it should be used cautiously. Patients with heart disease or impaired renal function should use this medication with caution, as concurrent use with opioid analgesics increases the risk of central nervous system depression. During early pregnancy, there is a risk of fetal malformations, so women who are pregnant or planning to become pregnant should consult a doctor and use effective contraception. Women who are breastfeeding should carefully assess whether to breastfeed due to the possibility of this medication being transmitted through breast milk and the necessity of treatment. It is advisable to avoid hazardous activities such as driving or operating machinery until dizziness or drowsiness fully subsides. This medication may cause serious skin reactions, so if any skin abnormalities such as rashes or blisters appear, discontinue use immediately and inform a healthcare provider. In the event of overdose, symptoms such as confusion, drowsiness, and depression may occur, and hemodialysis may be required if necessary. Keep this medication out of reach of children and avoid transferring it to other containers.
Not everyone experiences these, and they can vary from person to person.
This medicine should be stored in a tightly sealed container to protect it from air and moisture, and it is best kept in a cool place between 15 and 30 degrees Celsius. Storing it this way will help maintain the efficacy of the medication.
Hard capsules with a reddish-brown upper part and a white lower part containing white powder
30 capsules/bottle, 60 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 75mg
Hard capsule · Prescription medication
BC World Pharma Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.